Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
50%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
3
50%
Ph early_phase_1
1
17%
Ph phase_1
2
33%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 12 (33.3%)
Phase 23 (50.0%)

Trials by Status

terminated233%
completed467%

Recent Activity

Clinical Trials (6)

Drug Details

Intervention Type
DRUG
Total Trials
6